Peter J. Pitts
Research Subjects
Peter J. Pitts has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gregory A. Poland
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications Hervé Le Louet
Head of Pharmacovigilance Department, Henri Mondor/Assistance Publique Hôpitaux de Paris Université Paris est Creteil, Creteil, France
3 shared publicationsEmily Freeman
Patient Insights, Lundbeck, Indianapolis, USA
2 shared publicationsFrançois Houÿez
EURORDIS, Paris, France
2 shared publicationsGregory Katz
Chair of Innovation Management & Healthcare Performance, School of Medicine, Paris-Descartes University, Paris, France
1 shared publicationHervé Le Louët
Council for International Organizations of Medical Sciences (CIOMS), Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
- 21 July 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (6) , 1238-1244
Transforming Objective Participatory Patient Advocacy
Objective Participatory Patient Advocacy (OPPA) is an important evolution from traditional patient advocacy to a strategic, data-driven approach that significantly impacts the patient voice vis-a-vis both drug development and the regulatory processes, particularly within the realm of rare diseases. Focusing on the exemplar of Parent Project Muscular Dystrophy (PPMD) and its work in Duchenne muscular dystrophy (DMD), this article highlights how OPPA leverages scientific rigor, collaborative partnerships, and a patient-centered perspective to accelerate the development and approval of effective therapies. The era of anecdote-driven advocacy is waning, making way for a new paradigm where patient advocacy organizations act as pivotal stakeholders in the drug development ecosystem. OPPA is characterized by its use of data-driven tools such as surveys, preference studies, and real-world evidence to inform research priorities, clinical trial designs, and regulatory decision-making. By adopting this objective approach, patient advocacy groups can contribute valuable insights into patient needs, preferences, and risk tolerance, which can then be integrated into the drug development process to ensure that therapies are both effective and aligned with patient values. These initiatives encompass a wide range of activities, including investing in cutting-edge research, advocating for legislative support for intramural research, and fostering collaborative partnerships with researchers, industry stakeholders, and regulatory agencies. PPMD’s efforts to identify and validate biomarkers, map proteins, and develop industry guidance demonstrate its commitment to building a solid scientific foundation for DMD drug development. A key focus of the article is the collaborative effort between the FDA, PPMD, care-givers, healthcare providers, scientists, and regulatory experts to and the FDA, culminating in the creation of patient-initiated draft guidance for industry developing DMD therapies. This achievement signifies a shift in the regulatory landscape, with the FDA recognizing patient perspectives that has led to more flexible and patient-centered regulatory pathways and the approval of promising new therapies. Objective Participatory Patient Advocacy calls for continued collaboration between advocacy groups, regulators, industry, and researchers. These partnerships are essential to sustaining progress and ensuring meaningful outcomes. The lessons learned from PPMD’s experience offer a roadmap for other rare disease communities to emulate, paving the way for a future where patient voices are central to the development of innovative therapies and the improvement of patient care.
- 21 July 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (6) , 1238-1244
Open AccessTransforming Objective Participatory Patient Advocacy
Objective Participatory Patient Advocacy (OPPA) is an important evolution from traditional patient advocacy to a strategic, data-driven approach that significantly impacts the patient voice vis-a-vis both drug development and the regulatory processes, particularly within the realm of rare diseases. Focusing on the exemplar of Parent Project Muscular Dystrophy (PPMD) and its work in Duchenne muscular dystrophy (DMD), this article highlights how OPPA leverages scientific rigor, collaborative partnerships, and a patient-centered perspective to accelerate the development and approval of effective therapies. The era of anecdote-driven advocacy is waning, making way for a new paradigm where patient advocacy organizations act as pivotal stakeholders in the drug development ecosystem. OPPA is characterized by its use of data-driven tools such as surveys, preference studies, and real-world evidence to inform research priorities, clinical trial designs, and regulatory decision-making. By adopting this objective approach, patient advocacy groups can contribute valuable insights into patient needs, preferences, and risk tolerance, which can then be integrated into the drug development process to ensure that therapies are both effective and aligned with patient values. These initiatives encompass a wide range of activities, including investing in cutting-edge research, advocating for legislative support for intramural research, and fostering collaborative partnerships with researchers, industry stakeholders, and regulatory agencies. PPMD’s efforts to identify and validate biomarkers, map proteins, and develop industry guidance demonstrate its commitment to building a solid scientific foundation for DMD drug development. A key focus of the article is the collaborative effort between the FDA, PPMD, care-givers, healthcare providers, scientists, and regulatory experts to and the FDA, culminating in the creation of patient-initiated draft guidance for industry developing DMD therapies. This achievement signifies a shift in the regulatory landscape, with the FDA recognizing patient perspectives that has led to more flexible and patient-centered regulatory pathways and the approval of promising new therapies. Objective Participatory Patient Advocacy calls for continued collaboration between advocacy groups, regulators, industry, and researchers. These partnerships are essential to sustaining progress and ensuring meaningful outcomes. The lessons learned from PPMD’s experience offer a roadmap for other rare disease communities to emulate, paving the way for a future where patient voices are central to the development of innovative therapies and the improvement of patient care.
- 24 January 2024
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 38 (2) , 75-77
Female Problems: Women’s Health Mustn’t be Ghettoized in the Uterus
- 24 January 2024
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 38 (2) , 75-77
Female Problems: Women’s Health Mustn’t be Ghettoized in the Uterus
- Open Access
- 12 April 2023
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 16 (3) , 179-181
The Pogo-ization of Post-Pandemic Vaccine Policy
- 12 April 2023
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 16 (3) , 179-181
Open AccessThe Pogo-ization of Post-Pandemic Vaccine Policy
- 20 September 2022
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 15 (6) , 611-613
Regulating Between the Notes: The US FDA and the Evolution of the Patient Voice Through Twenty-First Century Regulatory Science
- 20 September 2022
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 15 (6) , 611-613
Regulating Between the Notes: The US FDA and the Evolution of the Patient Voice Through Twenty-First Century Regulatory Science
- 11 August 2022
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (1) , 100-103
Twenty-First Century Global ADR Management: A Need for Clarification, Redesign, and Coordinated Action
Adverse drug reactions (ADRs) are estimated to be between the fourth and sixth most common cause of death worldwide, taking their place among other prevalent causes of mortality such as heart disease, cancer, and stroke. ADRs impact a broad range of populations across a wide variety of global geography and demographics, with significant mortality and morbidity burden in vulnerable groups such as older people, pediatric populations, and individuals in low-income settings. Too large a share of medicines risk management remains limited to signal detection in big ADR databases (USFDA, EMA, WHO, etc.) This resource allocation is antiquated and applied statistical signal detection methodologies have reached their limits of usefulness. In addition, existing databases are designed for short-term reactions, closely related to medication use and, thus, can only partially assess important broader consequences across geography, time, and clinical relevance. There is an urgent need change the dynamic. We need to identify (earlier and more regularly) many of the important but often overlooked or missed ADRs. Rather than assigning blame, we need to identify the root causes of the problem so they can be clearly addressed and fixed. The public health implications are profound—particularly as we recognize the importance of predicting and mitigating the next pandemic. Consequently, medicines risk management must be integrated within a broader global public health vision. To accomplish this, we need to develop the new tools and methodologies critical to assessing these public health imperatives.
- 11 August 2022
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (1) , 100-103
Twenty-First Century Global ADR Management: A Need for Clarification, Redesign, and Coordinated Action
Adverse drug reactions (ADRs) are estimated to be between the fourth and sixth most common cause of death worldwide, taking their place among other prevalent causes of mortality such as heart disease, cancer, and stroke. ADRs impact a broad range of populations across a wide variety of global geography and demographics, with significant mortality and morbidity burden in vulnerable groups such as older people, pediatric populations, and individuals in low-income settings. Too large a share of medicines risk management remains limited to signal detection in big ADR databases (USFDA, EMA, WHO, etc.) This resource allocation is antiquated and applied statistical signal detection methodologies have reached their limits of usefulness. In addition, existing databases are designed for short-term reactions, closely related to medication use and, thus, can only partially assess important broader consequences across geography, time, and clinical relevance. There is an urgent need change the dynamic. We need to identify (earlier and more regularly) many of the important but often overlooked or missed ADRs. Rather than assigning blame, we need to identify the root causes of the problem so they can be clearly addressed and fixed. The public health implications are profound—particularly as we recognize the importance of predicting and mitigating the next pandemic. Consequently, medicines risk management must be integrated within a broader global public health vision. To accomplish this, we need to develop the new tools and methodologies critical to assessing these public health imperatives.
- 18 October 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 14 (6) , 871
Authors’ Reply to Ibrahim and Nair’s Comment on: “Health Literacy: The Common Denominator of Healthcare Progress”
- 18 October 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 14 (6) , 871
Authors’ Reply to Ibrahim and Nair’s Comment on: “Health Literacy: The Common Denominator of Healthcare Progress”
- 7 July 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 14 (5) , 455-458
Health Literacy: The Common Denominator of Healthcare Progress
- 7 July 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 14 (5) , 455-458
Health Literacy: The Common Denominator of Healthcare Progress